Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1154 | Dapagliflozin 10 mg Wiki | 0.71 |
| drug44 | 2019-nCoV IgG/IgM Rapid Test Cassette Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D054058 | Acute Coronary Syndrome NIH | 0.29 |
| D051436 | Renal Insufficiency, Chronic NIH | 0.24 |
| D007674 | Kidney Diseases NIH | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.24 |
| HP:0000077 | Abnormality of the kidney HPO | 0.19 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
Description: To evaluate the dose response effect of AZD5718 on urine ACR at 20 weeks
Measure: Change from baseline in urine ACR to Week 20 Time: Week 1 to Week 20Description: To evaluate the dose response effect of AZD5718 on urine ACR at 12 weeks
Measure: Change from baseline in urine ACR to Week 12 Time: Week 1 to Week 12Description: To assess the safety and tolerability profile of AZD5718 treatment
Measure: Number of participants with adverse events and serious adverse events Time: Screening to Week 24Description: To evaluate the effect of AZD5718 on ambulatory blood pressure
Measure: Change from baseline in 24-hours mean systolic blood pressure to Week 12 Time: Week 1 to Week 12Description: To assess the PK of AZD5718 after repeated oral dosing for 20 weeks
Measure: Plasma concentrations of AZD5718 Time: Week 2 to Week 20Description: To assess the effect of AZD5718 on renal function
Measure: Change from baseline in estimated glomerular filtration rate (eGFR) to Week 12 Time: Week 1 to Week 12This is a multi-center study conducted at 13 sites in 3 countries (Singapore, New Zealand, and the United Kingdom). Approximately 360 patients with an acute myocardial infarction (AMI) will be randomized in a ratio of 1:1 ratio to receive AZD5718 125 mg or placebo for 12 months.
Description: Percent change in NCPV (in mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment
Measure: Change in noncalcified coronary artery plaque volume (NCPV) Time: Baseline (before treatment) and after 12 months of treatmentDescription: To assess whether AZD5718 reduces coronary inflammation
Measure: Change in CT pericoronary adipose tissue (PCAT) Time: Baseline (before treatment) and after 12 months of treatmentDescription: Percent change in total plaque volume (in mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment
Measure: Change in total plaque volume (mm3) Time: Baseline (before treatment) and after 12 months of treatmentDescription: Percent change in LVEF (%), as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment
Measure: Echocardiographic assessment: Change in left ventricular ejection fraction (LVEF) Time: Baseline (before treatment) and after 12 months of treatmentDescription: To assess the PK of AZD5718 after repeated oral dosing for 12 months
Measure: Plasma concentrations of AZD5718 Time: 12 monthDescription: To assess the pharmacodynamics (PD) effect of AZD5718 by assessment of u-LTE4 in AMI patients
Measure: Change in levels of urinary LTE4 (u-LTE4) Time: 12 monthsDescription: Percent change in low attenuation (<30 HU) plaque volume (mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment
Measure: Change in low attenuation plaque burden Time: Baseline (before treatment) and after 12 months of treatmentDescription: To assess the effect of AZD5718 on LTB4 levels in ex vivo stimulated human plasma by liquid chromatography-tandem mass spectrometry
Measure: Change in levels of ex vivo stimulated plasma leukotriene B4 (LTB4) Time: 12 monthsDescription: To assess the changes in circulating hs-CRP concentrations from baseline (before treatment) to after 12-month of treatment
Measure: Change in plasma hs-CRP concentration Time: Baseline (before treatment) and after 12 months of treatmentDescription: To assess the changes in circulating troponin concentrations from baseline (before treatment) to after 12-month of treatment
Measure: Change in plasma troponin concentration Time: Baseline (before treatment) and after 12 months of treatmentDescription: To assess the changes in circulating NT-proBNP concentrations from baseline (before treatment) to after 12-month of treatment
Measure: Change in plasma NT-proBNP concentration Time: Baseline (before treatment) and after 12 months of treatmentDescription: Percent change in LV global longitudinal strain, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment
Measure: Echocardiographic assessment: Change in LV global longitudinal strain Time: Baseline (before treatment) and after 12 months of treatmentDescription: Percent change in global circumferential strain, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment
Measure: Echocardiographic assessment: Change in global circumferential strain Time: Baseline (before treatment) and after 12 months of treatmentDescription: Percent change in longitudinal early diastolic strain rate, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment
Measure: Echocardiographic assessment: Change in longitudinal early diastolic strain rate Time: Baseline (before treatment) and after 12 months of treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports